Cardiotoxicity in Newly Diagnosed Acute Myeloid Leukemia Patients

Official record

Identifier

NCT07851012

Recruiting locations

Locations are not included in the offline baseline for this record. Open the official record to see the current site list.

Interventions studied

Not provided in the official record

Lead sponsor

Assiut University

Target enrolment

146 participants

Study type

OBSERVATIONAL

Phase

Not provided in the official record

Status

Not yet recruiting

First posted

Oct 1, 2026

Last updated on the registry

Oct 1, 2026

Age

16 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:•

* Age ≥16 years with newly diagnosed, histologically confirmed AML.Scheduled to receive either:- Cohort A (Intensive): Anthracycline-based induction - Cohort B (Non-Intensive): Venetoclax and / or Hypomethylating Agent based regimens
* Baseline LVEF ≥ 50% as measured by standard baseline echocardiography.
* Patient provided written, informed consent.

Exclusion Criteria:

* Prior history of anthracycline or venetoclax\_HMAs exposure.
* Pre-existing severe structural heart disease (e.g., severe valvular heart disease, ischemic cardiomyopathy, basal LVEF \<50%).
* Persistent hemodynamically unstable arrhythmias.
* Poor acoustic windows making reliable 2D-STE tracking impossible.

Indexed under

Leukemia